Skip to main content
. 2015 Jan 14;6(8):6105–6122. doi: 10.18632/oncotarget.3368

Figure 1. Increased expression of MCL1 in malignant areas of treatment-naïve prostate tissue.

Figure 1

(A, B) Immunohistochemistry for MCL1 expression was performed on a TMA arranged with samples from treatment-naïve PCa (tnPCa) patients undergoing radical prostatectomy. Stainings from cancerous areas of 86 patients and adjacent benign areas of 87 patients were evaluable. (A) Representative images of positive MCL1 staining from paired tissue specimens of malignant areas (tnPCa) with Gleason Score (GSC) 6, 7 and 8, and adjacent benign areas (Be) are shown. (B) MCL1 staining was evaluated by an uropathologist using the quickscore system and the resulting staining scores are illustrated in box and whiskers graphs. (C) MCL1 mRNA expression was determined in primary basal benign and malignant cells after sorting into stem/tumor-initiating cell (SC/TIC, CD133+, CD49bhi), transit amplifying (TA, CD49bhi) and committed basal (CB, CD49blo) populations. Benign (Be, n=4) and malignant (tnPCa, n=5) primary basal cells were isolated from tissue specimens of treatment-naïve PCa patients undergoing radical prostatectomy. All samples were grown in cell culture in vitro and SC/TIC, TA and CB subpopulations were isolated as previously described [43]. Samples were subjected to qRT-PCR analysis for MCL1. MCL1 mRNA expression was normalized to the housekeeper RPLP0 and is expressed as 2−dCt.